571 related articles for article (PubMed ID: 26539835)
1. Soluble Urokinase Receptor and Chronic Kidney Disease.
Hayek SS; Sever S; Ko YA; Trachtman H; Awad M; Wadhwani S; Altintas MM; Wei C; Hotton AL; French AL; Sperling LS; Lerakis S; Quyyumi AA; Reiser J
N Engl J Med; 2015 Nov; 373(20):1916-25. PubMed ID: 26539835
[TBL] [Abstract][Full Text] [Related]
2. Plasma Soluble Urokinase Plasminogen Activator Receptor (suPAR) and CKD Progression in Children.
Weidemann DK; Abraham AG; Roem JL; Furth SL; Warady BA
Am J Kidney Dis; 2020 Aug; 76(2):194-202. PubMed ID: 31987488
[TBL] [Abstract][Full Text] [Related]
3. Association of Serum Soluble Urokinase Receptor Levels With Progression of Kidney Disease in Children.
Schaefer F; Trachtman H; Wühl E; Kirchner M; Hayek SS; Anarat A; Duzova A; Mir S; Paripovic D; Yilmaz A; Lugani F; Arbeiter K; Litwin M; Oh J; Matteucci MC; Gellermann J; Wygoda S; Jankauskiene A; Klaus G; Dusek J; Testa S; Zurowska A; Caldas Afonso A; Tracy M; Wei C; Sever S; Smoyer W; Reiser J;
JAMA Pediatr; 2017 Nov; 171(11):e172914. PubMed ID: 28873129
[TBL] [Abstract][Full Text] [Related]
4. Soluble Urokinase Plasminogen Activator Receptor and Decline in Kidney Function in Autosomal Dominant Polycystic Kidney Disease.
Hayek SS; Landsittel DP; Wei C; Zeier M; Yu ASL; Torres VE; Roth S; Pao CS; Reiser J
J Am Soc Nephrol; 2019 Jul; 30(7):1305-1313. PubMed ID: 31171572
[TBL] [Abstract][Full Text] [Related]
5. Soluble Urokinase-Type Plasminogen Activator Receptor, Changes of 24-Hour Blood Pressure, and Progression of Chronic Kidney Disease.
Jhee JH; Nam BY; Lee CJ; Park JT; Han SH; Kang SW; Park S; Yoo TH
J Am Heart Assoc; 2021 Jan; 10(1):e017225. PubMed ID: 33325248
[TBL] [Abstract][Full Text] [Related]
6. Soluble urokinase-type plasminogen activator receptor and incident end-stage renal disease in Chinese patients with chronic kidney disease.
Lv L; Wang F; Wu L; Wang JW; Cui Z; Hayek SS; Wei C; Reiser J; He K; Zhang L; Chen M; Zhao MH
Nephrol Dial Transplant; 2020 Mar; 35(3):465-470. PubMed ID: 30124995
[TBL] [Abstract][Full Text] [Related]
7. Circulating suPAR levels are affected by glomerular filtration rate and proteinuria in primary and secondary glomerulonephritis.
Musetti C; Quaglia M; Cena T; Chiocchetti A; Monti S; Clemente N; Magnani C; Dianzani U; Stratta P
J Nephrol; 2015 Jun; 28(3):299-305. PubMed ID: 25185729
[TBL] [Abstract][Full Text] [Related]
8. Soluble Urokinase-Type Plasminogen Activator Receptor in Black Americans with CKD.
Luo S; Coresh J; Tin A; Rebholz CM; Chen TK; Hayek SS; Tracy M; Lipkowitz MS; Appel LJ; Levey AS; Inker LA; Reiser J; Grams ME
Clin J Am Soc Nephrol; 2018 Jul; 13(7):1013-1021. PubMed ID: 29903900
[TBL] [Abstract][Full Text] [Related]
9. NT-proBNP and troponin T and risk of rapid kidney function decline and incident CKD in elderly adults.
Bansal N; Katz R; Dalrymple L; de Boer I; DeFilippi C; Kestenbaum B; Park M; Sarnak M; Seliger S; Shlipak M
Clin J Am Soc Nephrol; 2015 Feb; 10(2):205-14. PubMed ID: 25605700
[TBL] [Abstract][Full Text] [Related]
10. Soluble Urokinase-type Plasminogen Activator Receptor (suPAR) and Impaired Kidney Function in the Population-based Malmö Diet and Cancer Study.
Schulz CA; Persson M; Christensson A; Hindy G; Almgren P; Nilsson PM; Melander O; Engström G; Orho-Melander M
Kidney Int Rep; 2017 Mar; 2(2):239-247. PubMed ID: 28367534
[TBL] [Abstract][Full Text] [Related]
11. Soluble Urokinase Plasminogen Activator Receptor Predicts Cardiovascular Events, Kidney Function Decline, and Mortality in Patients With Type 1 Diabetes.
Rotbain Curovic V; Theilade S; Winther SA; Tofte N; Eugen-Olsen J; Persson F; Hansen TW; Jeppesen J; Rossing P
Diabetes Care; 2019 Jun; 42(6):1112-1119. PubMed ID: 30885954
[TBL] [Abstract][Full Text] [Related]
12. Serum-soluble urokinase receptor levels do not distinguish focal segmental glomerulosclerosis from other causes of nephrotic syndrome in children.
Sinha A; Bajpai J; Saini S; Bhatia D; Gupta A; Puraswani M; Dinda AK; Agarwal SK; Sopory S; Pandey RM; Hari P; Bagga A
Kidney Int; 2014 Mar; 85(3):649-58. PubMed ID: 24429405
[TBL] [Abstract][Full Text] [Related]
13. The soluble urokinase receptor is not a clinical marker for focal segmental glomerulosclerosis.
Meijers B; Maas RJ; Sprangers B; Claes K; Poesen R; Bammens B; Naesens M; Deegens JK; Dietrich R; Storr M; Wetzels JF; Evenepoel P; Kuypers D
Kidney Int; 2014 Mar; 85(3):636-40. PubMed ID: 24402090
[TBL] [Abstract][Full Text] [Related]
14. Plasma Biomarkers of Tubular Injury and Inflammation Are Associated with CKD Progression in Children.
Greenberg JH; Abraham AG; Xu Y; Schelling JR; Feldman HI; Sabbisetti VS; Gonzalez MC; Coca S; Schrauben SJ; Waikar SS; Ramachandran VS; Shlipak MG; Warady B; Kimmel PL; Bonventre JV; Denburg M; Parikh CR; Furth S;
J Am Soc Nephrol; 2020 May; 31(5):1067-1077. PubMed ID: 32234829
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular Disease Biomarkers and suPAR in Predicting Decline in Renal Function: A Prospective Cohort Study.
Hayek SS; Ko YA; Awad M; Ahmed H; Gray B; Hosny KM; Aida H; Tracy MJ; Wei C; Sever S; Reiser J; Quyyumi AA
Kidney Int Rep; 2017 May; 2(3):425-432. PubMed ID: 29142970
[TBL] [Abstract][Full Text] [Related]
16. Circulating soluble urokinase plasminogen activator receptor levels and peripheral arterial disease outcomes.
Samman Tahhan A; Hayek SS; Sandesara P; Hajjari J; Hammadah M; O'Neal WT; Kelli HM; Alkhoder A; Ghasemzadeh N; Ko YA; Aida H; Gafeer MM; Abdelhadi N; Mohammed KH; Patel K; Arya S; Reiser J; Vaccarino V; Sperling L; Quyyumi A
Atherosclerosis; 2017 Sep; 264():108-114. PubMed ID: 28728756
[TBL] [Abstract][Full Text] [Related]
17. Soluble urokinase plasminogen activation receptor and long-term outcomes in persons undergoing coronary angiography.
Sommerer C; Zeier M; Morath C; Reiser J; Scharnagl H; Stojakovic T; Delgado GE; März W; Kleber ME
Sci Rep; 2019 Jan; 9(1):475. PubMed ID: 30679668
[TBL] [Abstract][Full Text] [Related]
18. Association of Multiple Plasma Biomarker Concentrations with Progression of Prevalent Diabetic Kidney Disease: Findings from the Chronic Renal Insufficiency Cohort (CRIC) Study.
Schrauben SJ; Shou H; Zhang X; Anderson AH; Bonventre JV; Chen J; Coca S; Furth SL; Greenberg JH; Gutierrez OM; Ix JH; Lash JP; Parikh CR; Rebholz CM; Sabbisetti V; Sarnak MJ; Shlipak MG; Waikar SS; Kimmel PL; Vasan RS; Feldman HI; Schelling JR;
J Am Soc Nephrol; 2021 Jan; 32(1):115-126. PubMed ID: 33122288
[TBL] [Abstract][Full Text] [Related]
19. Urokinase plasminogen activator receptor and its soluble form in common biopsy-proven kidney diseases and in staging of diabetic nephropathy.
Wu CZ; Chang LC; Lin YF; Hung YJ; Pei D; Chu NF; Chen JS
Clin Biochem; 2015 Dec; 48(18):1324-9. PubMed ID: 26162494
[TBL] [Abstract][Full Text] [Related]
20. A reassessment of soluble urokinase-type plasminogen activator receptor in glomerular disease.
Spinale JM; Mariani LH; Kapoor S; Zhang J; Weyant R; Song PX; Wong HN; Troost JP; Gadegbeku CA; Gipson DS; Kretzler M; Nihalani D; Holzman LB;
Kidney Int; 2015 Mar; 87(3):564-74. PubMed ID: 25354239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
